Literature DB >> 733451

Automimmune response to dopamine-receptor as a possible mechanism in the pathogenesis of Parkinson's disease and schizophrenia.

O Abramsky, Y Litvin.   

Abstract

Clinical and neuropharmacological evidence indicates the involvement of dopaminergic mechanisms in Parkinson's disease and schizophrenia, as well as in iatrogenic Parkinsonism and drug-induced schizophrenia-like syndrome. The evidence hitherto presented stresses the existence of a reversed relationship between Parkinson's disease and schizophrenia and implicates the possibility that dysfunction of dopamine-receptors may be a central phenomenon in both diseases. In view of the recent demonstration of two separate dopamine-receptors, it is postulated that a striatal receptor blockade may cause Parkinson's disease, whereas a limbic receptor blockade may result in schizophrenia. The recent discovery that several autoimmune diseases, such as myasthenia gravis, are the result of an immunopharmacological block at receptor sites, together with several observations of immunological disorders in Parkinson's disease and schizophrenia, suggests the possibility that certain types of Parkinson's disease and schizophrenia might be the consequence of an autoimmune blockade of striatal or limbic dopamine-receptors, respectively.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 733451

Source DB:  PubMed          Journal:  Perspect Biol Med        ISSN: 0031-5982            Impact factor:   1.416


  12 in total

Review 1.  Inflammation and adaptive immunity in Parkinson's disease.

Authors:  R Lee Mosley; Jessica A Hutter-Saunders; David K Stone; Howard E Gendelman
Journal:  Cold Spring Harb Perspect Med       Date:  2012-01       Impact factor: 6.915

2.  Influenza viruses induce autoantibodies to a brain-specific 37-kDa protein in rabbit.

Authors:  P Laing; J G Knight; J M Hill; A G Harris; J S Oxford; R G Webster; M A Markwell; S M Paul; C B Pert
Journal:  Proc Natl Acad Sci U S A       Date:  1989-03       Impact factor: 11.205

3.  Immunology, autoimmunity, and autoantibodies in Parkinson's disease.

Authors:  Michal Benkler; Nancy Agmon-Levin; Sharon Hassin-Baer; Oren S Cohen; Oscar-Danilo Ortega-Hernandez; Amalia Levy; Samuel-Datum Moscavitch; Martine Szyper-Kravitz; Maya Damianovich; Miri Blank; Joab Chapman; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2012-04       Impact factor: 8.667

4.  Evolution of studies on antireceptor antibodies and disease.

Authors:  P R Carnegie; I R Mackay
Journal:  Springer Semin Immunopathol       Date:  1982

Review 5.  Microglia-Mediated Inflammation and Neurodegenerative Disease.

Authors:  Ling Xu; Dan He; Ying Bai
Journal:  Mol Neurobiol       Date:  2015-12-10       Impact factor: 5.590

Review 6.  New immunological approaches in treating and diagnosing CNS diseases.

Authors:  Kathy Guo; Damir Janigro
Journal:  Pharm Pat Anal       Date:  2013-05

7.  Failure to detect dopamine receptor IgG autoantibodies in sera of schizophrenic patients. Short note.

Authors:  A von Kirchbach; E G Fischer; H H Kornhuber
Journal:  J Neural Transm       Date:  1987       Impact factor: 3.575

8.  Placental Barrier and Autism Spectrum Disorders: The Roles of Prolactin and Dopamine in the Developing Fetal Brain-Part II.

Authors:  Atmaram Yarlagadda; Ganesh Acharya; Jayaprada Kasaraneni; Christiane S Hampe; Anita H Clayton
Journal:  Innov Clin Neurosci       Date:  2019-11-01

9.  Probable neuroimmunological link between Toxoplasma and cytomegalovirus infections and personality changes in the human host.

Authors:  Martina Novotná; Jitka Hanusova; Jirí Klose; Marek Preiss; Jan Havlicek; Katerina Roubalová; Jaroslav Flegr
Journal:  BMC Infect Dis       Date:  2005-07-06       Impact factor: 3.090

10.  Inverse Association of Parkinson Disease With Systemic Lupus Erythematosus: A Nationwide Population-based Study.

Authors:  Feng-Cheng Liu; Wen-Yen Huang; Te-Yu Lin; Chih-Hao Shen; Yu-Ching Chou; Cheng-Li Lin; Kuen-Tze Lin; Chia-Hung Kao
Journal:  Medicine (Baltimore)       Date:  2015-11       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.